About Acurx Pharmaceuticals, Inc. - Common Stock (ACXP)
Acurx Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel antimicrobial therapies to combat bacterial infections, particularly those caused by antibiotic-resistant pathogens. The company is engaged in research and development of innovative drug candidates that address critical unmet medical needs in the treatment of serious infections. With a commitment to advancing therapeutic options, Acurx aims to improve patient outcomes through its proprietary drug formulations and scientific expertise. The company's efforts are geared toward not only treating existing infections but also preventing the spread of multidrug-resistant bacteria in healthcare settings. Read More
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Shares of Acurx Pharmaceuticals inc. (NASDAQ: ACXP) are up on Tuesday following the publication of favorable clinical trial results and increased attention on the stock's micro-cap status.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Power Metallic Mines Inc. (TSXV: PNPN, OTCQB: PNPNF ) has reached a historic milestone by securing the largest exploration license in Saudi Arabia’s Jabal Sayid Belt , marking a major step in the company’s global expansion strategy. The awarded Jabal Baudan project spans over 200 square kilometers , targeting copper, gold, and zinc in one of the Kingdom’s most mineral-rich regions.
NEW YORK CITY, NEW YORK / ACCESS Newswire / April 16, 2025 / New to The Street, a premier business television and media platform, is proud to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) for a new 6-month strategic campaign. The series will include long-form interviews airing as sponsored programming on Fox Business and Bloomberg Television, earned media placements, over 50 national commercials per month, and expanded visibility across New to The Street's 2.4M+ subscriber YouTube channel and digital networks.
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 14, 2025 / The highly anticipated Visionaries Series from New to The Street and Sight & Sound premieres tomorrow on Bloomberg at 6:30 PM EST as sponsored programming, featuring Acurx Pharmaceuticals. This compelling episode follows the incredible journey of co-founders David P. Luci, Robert J. DeLuccia, and Robert G. Shawah - from their college days to building and exiting successful pharmaceutical companies, and ultimately coming together to launch Acurx Pharmaceuticals.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
